Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype

Oncol Rep. 2002 Mar-Apr;9(2):379-82.

Abstract

We investigated the effect of toremifene, interferon-alpha2a, interferon-alpha2b and interferon-alpha2c, singly and in combination for their effect on the growth of ZR-75-1 human breast cancer cells. Median effect analysis was used to determine synergistic or additive effects. Anti-proliferative studies showed that the growth of ZR-75-1 cells was inhibited to a greater extent by combination treatment with toremifene plus interferon-alpha2a, resulting in a synergistic interaction (CI <1) for all concentrations tested. A combination of toremifene plus interferon-alpha2b resulted in a synergistic interaction (CI <1) for the two highest concentrations of toremifene (10(-6) and 10(-7) M) and an additive effect (CI approximately equal to 1) for the lower concentrations (10(-8) to 10(-10) M). When toremifene was combined with interferon-alpha2c no additive or synergistic interaction was determined.

MeSH terms

  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Breast Neoplasms / drug therapy*
  • Cell Division / drug effects
  • Cell Line
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Synergism
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / pharmacology*
  • Recombinant Proteins
  • Toremifene / pharmacology*
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents, Hormonal
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Toremifene
  • interferon alfa-2c